Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma

Key Points

• The use of platinum-based chemotherapy did not improve survival rates among patients with metastatic pancreatic ductal adenocarcinoma.
• Only modest increases in treatment-related toxicities were associated with platinum regimens compared to non-platinum options.
• This observational analysis highlights the need for careful evaluation of chemotherapy effectiveness in heavily pretreated patients.
• Further research may be necessary to optimize treatment options for this patient population.

Abstract